Drugs / KRAS Neoantigen Nanovaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07353645 | Mar 2026 → Jan 2029 expected | colorectal cancer, malignant pancreatic neoplasm | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRAS Neoantigen Nanovaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07353645 ↗ |
| Modality | Vaccine | “neoantigen nanovaccine constructed from the bacterial membranes of engineered Lactococcus lactis” NCT07353645 ↗ |
| Route | Subcutaneous | “administered via subcutaneous or intralymph node injection” NCT07353645 ↗ |
| Target | KRAS | “expresses KRAS antigenic peptides” NCT07353645 ↗ |